VEGFR2 (vascular endothelial growth factor receptor 2) antagonist is an antineoplastic agent that blocks the binding of natural VEGF ligands, which are secreted by solid tumors to promote angiogenesis ...

Eva Madrid, the Lead of Cochrane’s new Iberoamérica Evidence Synthesis Unit, spoke on the panel of the launch event for the ...

Since COVID was first reported in December 2019, there have been more than 775 million recorded infections and more than 7 ...

Dr. Barry Davies joins Mosaic Therapeutics as CSO, bringing 25 years of drug discovery expertise to advance targeted oncology therapies and precision medicine.

Significant investments in digital health, telemedicine, and Artificial Intelligence (AI)-driven diagnostics have reshaped ...

The global lab automation market, valued at USD 2.1 billion in 2023, is poised for significant growth over the next decade, with projections estimating an increase to USD 5.5 billion by 2033. A recent ...

The current expectation is that every ovulatory menstrual cycle will have a luteal phase (the time from egg released until ...

After decades of studies, University of the Philippines Manila (UPM) researchers have developed a medicinal tablet made from ...

A cancer vaccine that had little success in clinical trials for patients with advanced tumors could potentially have efficacy ...

Doctors have long believed the cancer drug 5-fluorouracil works by damaging the building blocks of DNA, but researchers have now found that in certain cancers, it kills cells by interfering with RNA ...

One of the cornerstones of being prepared for the next pandemic is being in the best position possible to design and deploy a ...